U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07513454) titled 'A Phase 2 Study of HW211026 in Participants With Actinic Keratosis' on March 31.
Brief Summary: This is a multicenter, randomized, open-label, parallel-group, Phase II clinical trial designed to evaluate the efficacy and safety of HW211026 in adult patients with actinic keratosis.
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
Actinic Keratosis
Intervention:
DRUG: HW211026
HW211026 ointment dose 1，applied topically on face once daily.
DRUG: HW211026
HW211026 ointment dose 2，applied topically on face once daily.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hubei Bio-Pharmaceutical Indust...